Overview

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
axicabtagene ciloleucel
glofitamab
obinutuzumab
relmacabtagene autoleucel